Anzeige
Mehr »
Login
Sonntag, 16.06.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Sensationelle News: Hat East Africa bisher nur an der Oberfläche gekratzt?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853849 | ISIN: JP3463000004 | Ticker-Symbol: TKD
Tradegate
14.06.24
17:45 Uhr
24,460 Euro
+0,010
+0,04 %
Branche
Chemie
Aktienmarkt
NIKKEI-225
Singapur
1-Jahres-Chart
TAKEDA PHARMACEUTICAL CO LTD Chart 1 Jahr
5-Tage-Chart
TAKEDA PHARMACEUTICAL CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
24,24024,63015.06.
24,40024,50014.06.
ACCESSWIRE
485 Leser
Artikel bewerten:
(2)

Inspire and Takeda Researchers to Present Novel Study on Short Bowel Syndrome Patient Experience at DDW2024

WASHINGTON, DC / ACCESSWIRE / May 21, 2024 / Inspire, the world's largest health community and real-world evidence platform, has announced that it will present new research at Digestive Disease Week (DDW) 2024, unveiling insights from a mixed-method study on Short Bowel Syndrome (SBS) patient experience.

Inspire

Inspire



The study, conducted by researchers from Inspire in collaboration with Takeda, sheds light on the physical, social, and emotional burdens faced by SBS patients and their caregivers.

SBS is a condition in which the body can't absorb enough nutrients because part of the small intestine is missing or damaged, often due to surgical resection, congenital disability, or small intestine diseases. This condition profoundly impacts patients' lives, affecting their ability to meet nutritional needs and leading to long-term reliance on parenteral nutrition (PN).

The study employed a multidisciplinary approach to understand the complexities of SBS.

Lead researcher Josh Feldman, associate director of research at Inspire, emphasized the importance of longitudinal research in understanding and addressing the needs of the SBS population. "This study underscores the critical need for comprehensive support and interventions to improve the lives of individuals with SBS and their caregivers," said Feldman.

"Our collaboration with Inspire underscores Takeda's commitment to addressing the unmet needs of patients living with complex gastrointestinal conditions," said Vijay Yajnik, M.D., Ph.D., vice president, head of U.S. Medical for Gastroenterology, Takeda. "By leveraging real-world patient insights, we are better positioned to drive innovation and develop patient-centered resources, with the goal of improving outcomes for those affected by Short Bowel Syndrome."

Key findings from the study include:

Quality of Life (QOL) Impact: SBS patients reported a severe impact on their ability to work and travel, with a majority experiencing relatively poor QOL. Factors such as body mass index and household income significantly influenced patients' QOL scores.

Financial Constraints and Employment Issues: Patients and caregivers faced increased financial burdens and employment challenges due to inadequate insurance coverage and high healthcare costs.

Social Determinants of Health (SDOH) and Mental Health: The study revealed prevalent SDOH and mental health concerns among SBS patients, including difficulties in maintaining housing stability and high rates of depression among both patients and caregivers.

Causes and Diagnosis of SBS: Functional gastrointestinal disorders and surgeries were identified as common factors leading to SBS diagnosis, highlighting the need for improved diagnostic and treatment approaches.

The poster presentation will take place at DDW 2024, held in Washington, D.C. from May 18-21, 2024. Researchers from Inspire will be available to discuss the study findings and implications for future research and clinical practice.

About Inspire

Inspire is the world's largest online health community, patient engagement and real-world data platform. More than 10 million people each year come to Inspire to learn about their conditions and find peer support. Inspire also works with leading biopharmaceutical companies and academic researchers to provide real-world evidence and insights about the patient experience, connect patients with life-advancing clinical trials and enable medical breakthroughs. about.Inspire.com.

Contact Information

Lily McCutchan
Sr. Director, Marketing and Communications
lily.mccutchan@inspire.com
212-461-1128

SOURCE: Inspire

.

View the original press release on newswire.com.

KI-Champions: 3 Top-Werte, die Ihr Portfolio revolutionieren
Fordern Sie jetzt den brandneuen kostenfreien Sonderreport an und erfahren Sie, wie Sie von den enormen Wachstumschancen im Bereich Künstliche Intelligenz profitieren können - 100 % kostenlos.
Hier klicken
© 2024 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.